Oxazolidinone derivatives
CA 2393217 A1 · Owner: Merck Patent Gesellschaft Mit Beschraenkter Haftung · Inventors: Tsaklakidis, Christos; Buhring, Karl-Ulrich; Goodman, Simon
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of formula (I), wherein R1, R2 and n have the meanings give in claim N~1, and their physiologically compatible salts and solvates can be used as GP IIbIIIa antagonists for combating thromboses osteoporosis, oncosis, apoplexy, cardiac infarction ischemia, infections, arteriosclerosis and osteolytic diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.